Omega Pacific Resources Inc is engaged in the business of mineral exploration in Canada. It mainly engages in the acquisition, exploration, and development of mineral exploration properties. It holds an interest in the Lekcin property located in the New Westminster Mining Division, British Columbia, Canada.
相关临床试验
1
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2016
终止
1
100.0%
暂无批准数据
- Alloy Therapeutics appointed Christian Cobaugh, Ph.D., as CEO of its Genetic Medicines division to lead development of AntiClastic nucleic acid medicines targeting diseases at the genetic level. - The proprietary AntiClastic cyclic nucleic acid technology demonstrates improved potency and reduced inflammatory responses compared to traditional antisense oligonucleotides and siRNA formats. - Cobaugh brings over 15 years of genetic medicines leadership experience, including roles at CRISPR Therapeutics, Arcturus Therapeutics, and as founding CEO of Vernal Biosciences. - The AntiClastic platform integrates AI-based sequence design with validated oligonucleotide synthesis to advance partnered programs from therapeutic concepts to development candidates.
• Omega Therapeutics announces plans to file Chapter 11 bankruptcy following the suspension of its lead cancer drug program OTX-2002, with Flagship's Pioneering Medicines offering a $1.4 million bridge loan. • The genetic medicines company received a Nasdaq delisting notice in January 2024, marking a significant downturn since its $126 million IPO in 2021. • As part of restructuring, Omega will lay off 17 employees while negotiating asset sales, including its obesity program partnership with Novo Nordisk.
• GSK and Flagship Pioneering have established a strategic partnership worth potentially $7 billion to develop 10 new medicines and vaccines, with an initial focus on respiratory and immunological diseases. • The collaboration begins with a joint investment of $150 million, with each program eligible for up to $720 million in milestone payments plus royalties from GSK. • This partnership follows Flagship's successful collaborations with other major pharmaceutical companies, including Pfizer and Novo Nordisk, reinforcing their platform-based biotech development model.
